Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Fleur van der Sijde

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0634-4918; OpenAlex author ID A5087646037. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper

Papers 13

  1. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Co-author DOI 10.1016/j.ejca.2023.113440↗
  2. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2022.12.024↗
  3. Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15174349↗
  4. Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Co-author DOI 10.1007/s00520-021-06648-1↗
  5. Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Co-author DOI 10.1155/2022/8549487↗
  6. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498↗
  7. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System. Co-author DOI 10.1097/mpa.0000000000001862↗
  8. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1681↗
  9. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704↗
  10. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicente… Co-author DOI 10.3390/ijms222010902↗
  11. Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.cca.2020.03.005↗
  12. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Co-author DOI 10.3390/app9224784↗
  13. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers11010093↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 13 shared papers, 2019–2024 · strength 1.92
  2. Dana A. M. Mustafa · 9 shared papers, 2019–2024 · strength 1.36
  3. Eveline E. Vietsch · 9 shared papers, 2019–2024 · strength 1.21
  4. Bas Groot Koerkamp · 7 shared papers, 2019–2023 · strength 0.92
  5. Marjolein Y.V. Homs · 5 shared papers, 2021–2023 · strength 0.68
  6. Marc G. Besselink · 5 shared papers, 2019–2022 · strength 0.61
  7. Casper W.F. van Eijck · 3 shared papers, 2023–2024 · strength 0.59
  8. Johanna W. Wilmink · 4 shared papers, 2021–2022 · strength 0.50
  9. Brigitte C.M. Haberkorn · 4 shared papers, 2021–2022 · strength 0.50
  10. Gaby J. Strijk · 2 shared papers, 2023–2024 · strength 0.40
  11. Willem de Koning · 2 shared papers, 2023 · strength 0.38
  12. Freek R. van ‘t Land · 2 shared papers, 2021–2022 · strength 0.30
  13. Quisette P. Janssen · 2 shared papers, 2021–2022 · strength 0.23
  14. Bert A. Bonsing · 2 shared papers, 2021 · strength 0.21
  15. Marcella Willemsen · 1 shared paper, 2024 · strength 0.21
  16. Laura Schafthuizen · 1 shared paper, 2022 · strength 0.17
  17. Hanneke W.M. van Laarhoven · 1 shared paper, 2022 · strength 0.17
  18. Peter D. Katsikis · 1 shared paper, 2021 · strength 0.17
  19. Jacob L. van Dam · 1 shared paper, 2022 · strength 0.16
  20. Yunlei Li · 1 shared paper, 2020 · strength 0.15
  21. Elham Aïda Farshadi · 1 shared paper, 2021 · strength 0.13
  22. Michail Doukas · 1 shared paper, 2021 · strength 0.13
  23. Ivana Peran · 1 shared paper, 2019 · strength 0.10
  24. Mustafa Suker · 1 shared paper, 2019 · strength 0.10
  25. Anton Wellstein · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.